CLOTASSIST.CA
Information for
Health Care Providers
Our pharmacists can initiate therapy of low molecular weight heparin (LMWH) for cancer patients with a stable clot, or to prevent clots in pregnant women. Take advantage of our services to improve patient care.
LMWH for cancer associated thrombosis
Initiating treatment for patients with cancer associated thrombosis is now easier than ever before. Our pharmacists will:
-
review labwork and reconcile meds
-
weigh the patient
-
initiate therapy with low weight molecular heparin x 14 days *physician to renew rx within 14 days*
-
administer the first dose and train the patient on self-administration using a bruiseless subcutaneous injection technique
-
follow up by phone the next day
-
order a lab requisition to monitor platelets for heparin-induced thrombocytopenia
-
Communicate a summary to the patient's family physician and their oncologist.
​
The pharmacist will contact the referring oncologist before proceeding if:
-
labwork is over 14 days old, and no new labwork was completed with results pending
-
platelet count is below 50 000
-
clotting or bleeding disorder that was not identified on the form completed by the oncologist
-
patient is taking warfarin and INR is over 3, or no labwork in the past 14 days
​
​
LWMH for Thromboprophylaxis in Pregnancy
Our pharmacists have received specialized training to initiate therapy for thromboprophylaxis in pregnancy. On referral, the pharmacist will:
-
review labwork and reconcile meds, order baseline labwork if needed
-
weigh the patient
-
initiate therapy with low weight molecular heparin x 10 weeks
-
administer the first dose and train the patient on self-administration using a bruiseless subcutaneous injection technique
-
follow up by phone the next day
-
order a lab requisition to monitor platelets for heparin-induced thrombocytopenia
-
communicate a summary to the patient's family physician
​
​
​